Get definite about definitive drug tests to avoid the attention of auditors

Why This Topic Matters

Definitive drug testing claims can be closely scrutinized when denial patterns persist, so understanding the reporting framework and compliance expectations is important for reducing billing problems and audit exposure.

Article Sections

1. Medicare Part B billing concerns for definitive drug testing

   Introduces the denial and audit concerns surrounding definitive drug testing claims and explains why the topic is drawing attention from payers and investigators.

2. Definitive drug test reporting codes

   Summarizes the Medicare reporting framework for definitive drug testing and identifies the code set discussed in the article.

3. How definitive testing differs from presumptive testing

   Provides a general comparison of test types and describes how billing relationships between them can affect claim processing.

4. Coding updates, CLIA requirements, and frequency limits

   Covers the article’s discussion of implementation timing, laboratory certification considerations, and reported limits on how often these services may be billed.